Mocertatug Rezetecan for Endometrial Cancer

This trial tests a new treatment called mocertatug rezetecan (Mo-Rez) for endometrial cancer to determine its effectiveness compared to current treatments. Researchers aim to assess the efficacy and safety of Mo-Rez against standard treatments like doxorubicin and paclitaxel. The trial seeks participants diagnosed with endometrial cancer who have previously undergone chemotherapy without lasting results. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants an opportunity to contribute to potentially groundbreaking advancements in endometrial cancer treatment.

The trial requires that you stop taking certain medications before starting. Specifically, you must not have taken any cytotoxic chemotherapy or other antitumor drugs within 30 days or 5 half-lives before the trial, and you must stop inhibitors of certain proteins 7 days before the trial. Additionally, P-gp inducers should be stopped at least 14 days before the trial.

Research has shown that mocertatug rezetecan (Mo-Rez) underwent safety testing in previous studies. Common side effects include nausea (experienced by 86% of patients), tiredness (77%), a decrease in white blood cells (73%), low red blood cells (52%), and hair loss (52%). More serious side effects occurred in about 48% of patients with endometrial cancer. However, only about 3% of patients experienced lung-related issues like ILD/pneumonitis, which are more serious but less common. Overall, while some side effects occur frequently, the serious ones are less common.¹²³⁴⁵

Mocertatug rezetecan is unique because it represents a new approach to treating endometrial cancer. Unlike standard treatments like Paclitaxel and Doxorubicin, which generally work by interfering with cell division, Mocertatug rezetecan offers a novel mechanism that specifically targets cancer cells, potentially leading to more effective and personalized treatment. Researchers are excited about this treatment because it could provide better outcomes with fewer side effects, making it a promising option for patients who may not respond well to traditional therapies.

Research has shown that the drug mocertatug rezetecan (Mo-Rez), which participants in this trial may receive, holds promise for treating endometrial cancer. Studies have found that 67% of patients with recurring or advanced endometrial cancer experienced a reduction in tumor size, meaning more than half saw their tumors shrink. Mo-Rez targets a protein called B7-H4 on cancer cells, enabling the drug to attack and destroy these cells. The treatment has also proven effective in other cancer types, with manageable side effects. These findings suggest that Mo-Rez could be a strong option for those fighting endometrial cancer. Meanwhile, participants in the standard of care arm will receive either Paclitaxel or Doxorubicin, as determined by the investigator.¹²³⁴⁶